Morinamide

Last updated
Morinamide
Morinamide.svg
Clinical data
AHFS/Drugs.com International Drug Names
ATC code
Identifiers
  • N-(morpholin-4-ylmethyl)pyrazine-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard 100.012.237 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C10H14N4O2
Molar mass 222.248 g·mol−1
3D model (JSmol)
  • C1COCCN1CNC(=O)C2=NC=CN=C2
  • InChI=1S/C10H14N4O2/c15-10(9-7-11-1-2-12-9)13-8-14-3-5-16-6-4-14/h1-2,7H,3-6,8H2,(H,13,15)
  • Key:GVTLAVKAVSKBKK-UHFFFAOYSA-N
   (verify)

Morinamide (or morphazinamide, or morinamid) is a drug used in the treatment of tuberculosis. [1] It behaves as a prodrug for Pyrazinamide.

Related Research Articles

<span class="mw-page-title-main">BCG vaccine</span> Vaccine primarily used against tuberculosis

Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). It is named after its inventors Albert Calmette and Camille Guérin. In countries where tuberculosis or leprosy is common, one dose is recommended in healthy babies as soon after birth as possible. In areas where tuberculosis is not common, only children at high risk are typically immunized, while suspected cases of tuberculosis are individually tested for and treated. Adults who do not have tuberculosis and have not been previously immunized, but are frequently exposed, may be immunized, as well. BCG also has some effectiveness against Buruli ulcer infection and other nontuberculous mycobacterial infections. Additionally, it is sometimes used as part of the treatment of bladder cancer.

Colon classification (CC) is a library classification system developed by Shiyali Ramamrita Ranganathan. It was an early faceted classification system. The first edition of colon classification was published in 1933, followed by six more editions. It is especially used in libraries in India.

<span class="mw-page-title-main">Tuberculosis</span> Infectious disease

Tuberculosis (TB) is an infectious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis. Around 10% of latent infections progress to active disease which, if left untreated, kill about half of those affected. Typical symptoms of active TB are chronic cough with blood-containing mucus, fever, night sweats, and weight loss. It was historically referred to as consumption due to the weight loss associated with the disease. Infection of other organs can cause a wide range of symptoms.

<i>Mycobacterium tuberculosis</i> Species of pathogenic bacteria that causes tuberculosis

Mycobacterium tuberculosis, also known as Koch's bacillus, is a species of pathogenic bacteria in the family Mycobacteriaceae and the causative agent of tuberculosis. First discovered in 1882 by Robert Koch, M. tuberculosis has an unusual, waxy coating on its cell surface primarily due to the presence of mycolic acid. This coating makes the cells impervious to Gram staining, and as a result, M. tuberculosis can appear weakly Gram-positive. Acid-fast stains such as Ziehl–Neelsen, or fluorescent stains such as auramine are used instead to identify M. tuberculosis with a microscope. The physiology of M. tuberculosis is highly aerobic and requires high levels of oxygen. Primarily a pathogen of the mammalian respiratory system, it infects the lungs. The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, culture, and polymerase chain reaction.

<span class="mw-page-title-main">Isoniazid</span> Antibiotic for treatment of tuberculosis

Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis. For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol. For latent tuberculosis, it is often used alone. It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi. It is usually taken by mouth, but may be used by injection into muscle.

<i>Mycobacterium bovis</i> Species of bacterium

Mycobacterium bovis is a slow-growing aerobic bacterium and the causative agent of tuberculosis in cattle. It is related to Mycobacterium tuberculosis, the bacterium which causes tuberculosis in humans. M. bovis can jump the species barrier and cause tuberculosis-like infection in humans and other mammals.

<span class="mw-page-title-main">Rifamycin</span> Group of antibiotics

The rifamycins are a group of antibiotics that are synthesized either naturally by the bacterium Amycolatopsis rifamycinica or artificially. They are a subclass of the larger family of ansamycins. Rifamycins are particularly effective against mycobacteria, and are therefore used to treat tuberculosis, leprosy, and mycobacterium avium complex (MAC) infections.

<span class="mw-page-title-main">Rifampicin</span> Antibiotic medication

Rifampicin, also known as rifampin, is an ansamycin antibiotic used to treat several types of bacterial infections, including tuberculosis (TB), Mycobacterium avium complex, leprosy, and Legionnaires’ disease. It is almost always used together with other antibiotics with two notable exceptions: when given as a "preferred treatment that is strongly recommended" for latent TB infection; and when used as post-exposure prophylaxis to prevent Haemophilus influenzae type b and meningococcal disease in people who have been exposed to those bacteria. Before treating a person for a long period of time, measurements of liver enzymes and blood counts are recommended. Rifampicin may be given either by mouth or intravenously.

<span class="mw-page-title-main">Sanatorium</span> Medical facility for treatment of chronic illness

A sanatorium, also sanitarium or sanitorium, are antiquated names for specialised hospitals, for the treatment of specific diseases, related ailments and convalescence. Sanatoriums are often in a healthy climate, usually in the countryside. The idea of healing was an important reason for the historical wave of establishments of sanatoriums, especially at the end of the 19th- and early 20th centuries. One sought, for instance, the healing of consumptives, especially tuberculosis or alcoholism, but also of more obscure addictions and longings of hysteria, masturbation, fatigue and emotional exhaustion. Facility operators were often charitable associations such as the Order of St. John and the newly founded social welfare insurance companies.

<span class="mw-page-title-main">Tuberculosis management</span>

Tuberculosis management describes the techniques and procedures utilized for treating tuberculosis (TB).

<span class="mw-page-title-main">Tuberculosis verrucosa cutis</span> Medical condition

Tuberculosis verrucosa cutis is a rash of small, red papules and nodules in the skin that may appear two to four weeks after inoculation by Mycobacterium tuberculosis in a previously infected and immunocompetent individual.

<span class="mw-page-title-main">Pyrazinamide</span> Medication

Pyrazinamide is a medication used to treat tuberculosis. For active tuberculosis, it is often used with rifampicin, isoniazid, and either streptomycin or ethambutol. It is not generally recommended for the treatment of latent tuberculosis. It is taken by mouth.

<span class="mw-page-title-main">4-Aminosalicylic acid</span> Anti-tuberculosis and anti-inflammatory drug

4-Aminosalicylic acid, also known as para-aminosalicylic acid (PAS) and sold under the brand name Paser among others, is an antibiotic primarily used to treat tuberculosis. Specifically it is used to treat active drug resistant tuberculosis together with other antituberculosis medications. It has also been used as a second line agent to sulfasalazine in people with inflammatory bowel disease such as ulcerative colitis and Crohn's disease. It is typically taken by mouth.

Mycobacterium microti

Mycobacterium canettii, a novel pathogenic taxon of the Mycobacterium tuberculosis complex (MTBC), was first reported in 1969 by the French microbiologist Georges Canetti, for whom the organism has been named. It formed smooth and shiny colonies, which is highly exceptional for the MTBC. It was described in detail in 1997 on the isolation of a new strain from a 2-year-old Somali patient with lymphadenitis. It did not differ from Mycobacterium tuberculosis in the biochemical tests and in its 16S rRNA sequence. It had shorter generation time than clinical isolates of M. tuberculosis and presented a unique, characteristic phenolic glycolipid and lipo-oligosaccharide. In 1998, Pfyffer described abdominal lymphatic TB in a 56-year-old Swiss man with HIV infection who lived in Kenya. Tuberculosis caused by M. canettii appears to be an emerging disease in the Horn of Africa. A history of a stay to the region should induce the clinician to consider this organism promptly even if the clinical features of TB caused by M. canettii are not specific. The natural reservoir, host range, and mode of transmission of the organism are still unknown.

<span class="mw-page-title-main">Multidrug-resistant tuberculosis</span> Medical condition

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB).

<span class="mw-page-title-main">Isocitrate lyase</span>

Isocitrate lyase, or ICL, is an enzyme in the glyoxylate cycle that catalyzes the cleavage of isocitrate to succinate and glyoxylate. Together with malate synthase, it bypasses the two decarboxylation steps of the tricarboxylic acid cycle and is used by bacteria, fungi, and plants.

<span class="mw-page-title-main">Cord factor</span> Chemical compound

Cord factor, or trehalose dimycolate (TDM), is a glycolipid molecule found in the cell wall of Mycobacterium tuberculosis and similar species. It is the primary lipid found on the exterior of M. tuberculosis cells. Cord factor influences the arrangement of M. tuberculosis cells into long and slender formations, giving its name. Cord factor is virulent towards mammalian cells and critical for survival of M. tuberculosis in hosts, but not outside of hosts. Cord factor has been observed to influence immune responses, induce the formation of granulomas, and inhibit tumor growth. The antimycobacterial drug SQ109 is thought to inhibit TDM production levels and in this way disrupts its cell wall assembly.

<span class="mw-page-title-main">Tuberculosis in India</span> Health issue in India

Tuberculosis in India is a major health problem, causing about 220,000 deaths every year. In 2020, the Indian government made statements to eliminate tuberculosis from the country by 2025 through its National TB Elimination Program. Interventions in this program include major investment in health care, providing supplemental nutrition credit through the Nikshay Poshan Yojana, organizing a national epidemiological survey for tuberculosis, and organizing a national campaign to tie together the Indian government and private health infrastructure for the goal of eliminating the disease.

<span class="mw-page-title-main">Prisons in Russia</span> Prison system in Russia

Prisons in Russia consist of four types of facilities: pre-trial institutions; educative or juvenile colonies; corrective colonies; and prisons.

References

  1. Bonanni G, Ciccariello M, Mancini P, Pace V, Sagliaschi G (1993). "Concomitant ceco-appendicular and urinary tuberculosis. Description of two rare cases: physiopathological and diagnostic remarks". Riv Eur Sci Med Farmacol. 15 (3–4): 171–4. PMID   7761665.